Precision medicine is transforming kidney cancer treatment by tailoring therapies to each patient’s tumor genetics and molecular profile. Genetic and molecular profiling identifies mutations and pathways driving tumor growth, guiding targeted drugs like the HIF-2α inhibitor belzutifan. Personalized cancer vaccines are emerging, using tumor-specific neoantigens to train the immune system, with early trials showing some patients remain cancer-free for years. Predictive biomarkers further refine therapy selection, helping identify which patients will respond to immunotherapy or targeted combinations.
Surgical approaches have also advanced. Minimally invasive and robotic-assisted surgery reduces pain, blood loss, and recovery time, while partial nephrectomy preserves kidney function by removing only the tumor and a small margin of healthy tissue. These techniques are increasingly applied to complex tumors safely.
Comprehensive care integrates surgery with systemic therapies. Neoadjuvant targeted therapy or immunotherapy can shrink tumors pre-surgery, and adjuvant immunotherapy post-surgery eliminates residual cancer cells, becoming the standard for high-risk patients.